In Tough Economic Times, What's A New Science Grad To Do?

The current recession has not spared professionals, and 1991-92 has been a difficult year for young scientists attempting to leave university campuses for permanent positions, whether in industry or academia. As career advisers to young scientists for a combined total of 15 years, we have never seen a year in which so many scientists have expressed doubts about continuing in research as it has traditonally been conducted. On the other hand, we have also spoken with employers offering opportunit

Written byMary Morris Heiberger
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

We have learned that many scientists tend to feel that successful careers inevitably follow successful research. In the present environment, such an attitude is a luxury that most candidates can ill afford. New scientists who take the time to understand the present market and future trends, and who position themselves intelligently, as suggested below, are much more likely to be the beneficiaries, rather than the victims, of change.

In 1991-92, hiring was slow. When a company is in financial difficulty, it is always tempting to cut research expenditures, including salaries paid to staff scientists. As a result, on-campus recruiting has been curtailed across the United States this year, and companies have been making fewer offers.

In addition, some of the corporate giants that regularly recruit new scientists have been downsizing. Thus, junior scientists who have lost their jobs have been added to the normal pool of new Ph.D.'s and recent ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies